relapsing-remitting MS active secondary progressive MS The drug comes as a solution for injection. The active ingredient in Briumvi is ublituximab-xiiy. Briumvi belongs to a group of drugs called ...

WHEN life gave Lina Nielsen lemons, she sprinted straight to the Olympics.  The 28-year-old was diagnosed with multiple sclerosis at 17 years old, leaving her terrified of disability. Doctors gave ...

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, ...

Bleakley Financial Group LLC purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund purchased 8,140 shares of the ...

The Floodlight MS app, used to track disease progression in people with multiple sclerosis, has been deemed cost-effective in ...

Experts in Australia and New Zealand have published the first consensus guidelines for the care of adults with MS in those ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Abstract and Introduction Autonomic Reaction, the Anxiety Response, and Development of Phobic Symptoms Treatment of Self-Injection Anxiety Summary References Autonomic Reaction, the Anxiety ...

That said, more research is needed to examine the link between MS and dementia. Many disease-modifying therapies (DMTs) have been developed to slow the progression of MS. DMTs may help prevent or ...